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Abstract The relationship between the prevalence of
multiple sclerosis (MS) and sunlight’s ultraviolet radiation
was proved. Oxidative stress plays a role in the pathogenic
traits of MS. Melatonin possesses antioxidative properties
and regulates circadian rhythms. Sleep disturbances in MS
patients are common and contribute to daytime fatigue. The
aim of study was to evaluate 5 mg daily melatonin supple-
mentation over 90 days on serum total oxidant status (TOS),
total antioxidant capacity (TAC) and its influence on sleep
quality and depression level of MS patients. A case–control
prospective study was performed on 102 MS patients and 20
controls matched for age and sex. The Kurtzke’s Expanded
Disability Status Scale, magnetic resonance imaging exam-
inations, Athens Insomnia Scale (AIS), Beck Depression
Inventory questionnaires were completed. Serum TOS and
TAC levels were measured. We observed higher serum
levels of TOS in all MS groups, while after melatonin
treatment the TOS levels significantly decreased. The TAC
level was significantly lower only in mitoxantrone-treated
group and it increased after melatonin supplementation. A
strong positive correlation between T1Gd(?) number
lesions and TAC level in interferon-beta-1A group was
observed. AIS group mean score above 6 defining insomnia
were observed in interferon-beta-1B-group, glatiramer
acetate-group and mitoxantrone-group: 6.62 ± 2.88, 8.45 ±
2.07, 11.1 ± 3.25, respectively. After melatonin treatment
the AIS mean scores decrease in glatiramer acetate-group
and mitoxantrone-group achieving 5.25 ± 1.14 and
7.08 ± 2.39, respectively (p \ 0.05). Finding from our
study suggest that melatonin can act as an antioxidant and
improves reduced sleep quality in MS patients.
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Introduction
Multiple sclerosis (MS) is an immune-mediated, the most
prevalent demyelinating disease of the central nervous
system (CNS) in young adults. Environmental factors play
an important role in MS etiology. The relationship between
the prevalence of MS, latitude gradient, and sunlight’s
ultraviolet radiation was proved [1]. MS incidence is higher
in geographic regions with sunlight exposure deficiency.
Melatonin and vitamin D are mediators of the effects of
sunlight in healthy individuals, and both are thought to play
a role in MS pathophysiology [1, 2].
To date, the exact mechanisms of MS pathophysiology
remain to be fully explained, but a triad of neural tissue
injury mechanisms: inflammation, demyelination, and
axonal damage is still valid [3]. Recent studies have sug-
gested that oxidative stress can play a crucial role in the
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pathogenic traits of MS. The CNS is very susceptible to
oxidative damage [4, 5].
Melatonin (N-acetyl-5-methoxytryptamine) is a natural
hormone mainly produced in the mammalian pineal gland
during the dark phase. With its lipophilic and hydrophilic
character, melatonin freely crosses the blood–brain barrier
and enters all cells. Melatonin acts through G-protein coupled
membrane receptors, MT1 and MT2 and through nuclear
receptors RZR/ROR [6]. Both receptors are widely present in
the central and peripheral nervous systems, and have been
associated with cell differentiation and immune response
regulation. Moreover, melatonin receptors are expressed on
the membrane of CD4 T cells, CD8 T cells, and B cells [7].
Melatonin and its metabolites have been demonstrated to
possess multiple functions, including antioxidation, immu-
nomodulatory and anti-inflammatory effects [3, 8].
Melatonin influences antioxidative defensive systems,
up-regulates gene expression, and stimulates the activities
of several antioxidant enzymes, including glutathione
peroxidase (GSH-Px), superoxide dismutase (SOD), cata-
lase (CAT), as well as the levels of glutathione (GSH) [8–
11]. Melatonin has been shown to have immunomodulatory
properties involved in the regulation of both the cellular
and humoral immunity. The regulatory function of mela-
tonin on immune mechanisms is seasonally dependent. As
a consequence, melatonin improves the clinical course of
illnesses with inflammatory etiology [3, 12]. Moreover, it
participates in neurogenesis, regulation of circadian
rhythms, sleep, and also exerts an anti-tumor activity [3,
12, 13].
The important role of melatonin as a modulator of sleep
is well documented. Melatonin treatment can also entrain
the circardian clock and could be helpful in coping with
jet-lag and shift-work, as well as be useful in blind sub-
jects, and in individuals with delayed or advanced sleep
phase disorders. Administration of exogenous melatonin
has been reported to increase sleep quality and length, and
decrease sleep latency and the number of wakeful episodes
in elderly women with insomnia, as well as significantly
improve functioning the following day [12]. It is known
that sleep disturbances are present more often in MS
patients than in the general population and contribute to
daytime fatigue [14, 15]. There are only few original
papers concerning sleep problems in MS patients. The
prevalence of sleep problems was reported in 24–50 % of
MS patients [16, 17]. The possible common pathomecha-
nisms shared by MS and sleep disturbances may be con-
nected with circadian rhythm disorders with compromised
melatonin secretion reducing input to the suprachiasmatic
nucleus due to impaired visual pathways, as well as
increased levels of proinflammatory cytokines [18].
The role of melatonin in MS has been suggested in
several clinical studies. It was found that shift work at a
young age increases the risk of MS [19]. Melatonin levels
in saliva were significantly low among patients with MS
after controlling the effect of age. [20]. Moreover, it was
proved that melatonin and its immediate precursor N-ace-
tylserotonin decrease demyelination and increase remyeli-
nation under inflammatory conditions [21]. It was reported
that MS is associated with increased levels of depression,
which may lead to decreases in melatonin levels. It is
known that depression is also linked to sleep dysregulation.
Moreover depression is associated with decreased levels of
serotonin, which is a precursor for melatonin [22].
The aim of our present study was to evaluate the action of
melatonin as a molecule with antioxidative properties on the
total oxidant status (TOS) in serum and total antioxidant
capacity (TAC) levels in patients with MS, a disease with well-
documented oxidative stress disturbance pathology. More-
over, we also intended to ascertain the influence of melatonin
on sleep quality and depression levels of MS patients.
Materials and Methods
Patients
A case–control prospective study was performed on 102
MS diagnosed according to the McDonald criteria (2005)
[23] patients (69 women, 33 men) and 20 (13 women, 7
men) healthy subjects matched for age and sex, observed in
2013 in the Department of Neurology in Zabrze, Medical
University of Silesia, Poland. The patients were divided
into following groups:
Group C (control group) 20 healthy controls observed in
our Department due to undiagnosed headaches. Controls
were matched for age and sex with the study group.
Group P (pre-treated MS group) 21 patients with de
novo relapsing-remitting form of MS (RRMS), without
any immunomodifying MS treatment.
Group A (beta-1a interferons treated MS group) 25
patients with RRMS. All of them received interferon
beta-1a, applied once per week as an intramuscular
injection.
Group B (beta-1b interferons treated MS group) 27
patients with RRMS. All of them received interferon
beta-1b, injected subcutaneously every other day.
Group G (glatiramer acetate treated MS group) 12
patients with RRMS. All of them received daily
subcutaneous glatiramer acetate injections.
Group MX (mitoxantrone treated MS group) 17 patients
with secondarily progressive (SP) or progressive-
relapsing (PR) form of MS. All of them received 5
doses of mitoxantrone iv (12 mg/m2/dose) administered
quarterly.
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None of the patients received any antioxidative sub-
stances, vitamins, anti-inflammatory, or hormonal treat-
ment for at least 3 months prior to the study, and any
sleeping pills 2 weeks prior to the study.
Demographic characteristics of the patients were pre-
sented in Table 1.
Study Protocol
The study was approved by the local Ethics Committee of
the Medical University of Silesia (KNW/0022/KB1/130/
12).
After obtaining informed consent, demographic data,
Kurtzke’s Expanded Disability Status Scale (EDSS) [24],
Athens Insomnia Scale (ASI) and Beck Depression
Inventory (BDI) questionnaires were completed in all
groups. Head magnetic resonance imaging (MRI) exam-
inations were performed in all MS patients at the beginning
of the study, in accordance with standard clinical protocols.
The neurological examination was performed by a quali-
fied neurologist using the EDSS before the therapy and
after its completion. All MS patients were supplemented
orally with melatonin, 5 mg per day, over a period of
90 days. Before and after the melatonin supplementation,
the TOS and TAC values in the serum were measured.
Enzymatic Assays
Ten milliliter samples of venous blood, before and after the
90 days of melatonin supplementation, were collected from
the MS patients between 6.00 and 7.00 a.m., centrifuged
and frozen until laboratory measurements were performed.
The TOS of the serum was measured using an auto-
mated calorimetric method according to Erel [25]. The
results were expressed in terms of micromolar hydrogen
peroxide equivalent per liter (lmol H2O2 equivalent/L).
The TAC was measured according to Erel [26]. The
achieved results were expressed as mmol Trolox equiva-
lent/L.
All laboratory analyses were performed at the Depart-
ment of Biochemistry in Zabrze, Medical University of
Silesia.
Questionnaires
The sleep conditions were evaluated using the Polish val-
idated reliable version of AIS questionnaire as a self-ass-
esement tool designed to measure sleep difficulty. AIS
defines insomnia based on the ICD-10 criteria. AIS consists
of eight items inquiring about sleep conditions over the
previous month. The first five items assess sleep difficulties
with regard to the quantity and quality of sleep: difficulties
falling asleep, maintaining sleep, early morning awaking,
total sleep duration and sleep quality. The last three items
assess the following-day consequences of sleep or daytime
symptoms, which may result from insomnia and/or a sleep
disorder: subjective well-being, functioning capacity and
sleepiness during the day. Each item of the AIS is rated on
a scale from 0 (no problem at all) to 3 (a very serious
problem) with the maximum score of 24; a score of 6 or
more points indicating insomnia. The original validation
study demonstrated good internal, test–retest reliability and
external validity [27]. Validation of the Polish version AIS
was performed in 2011. The internal consistency (Cron-
bach’s a = 0.90) and the test–retest reliability (r2 = 0.92)
of the AIS were found to be very satisfactory [28].
The BDI is an instrument for the evaluation of depres-
sion [29]. It is composed of 21 items rated on a scale from
0 to 3. Patients with scores between 0 and 9 are not rec-
ognized as depressed, scores between 10 and 18 indicate
mild to moderate depression, scores above 19 mean mod-
erate to severe depression. The valid Polish version of BDI
was applied in our study [30].
MRI Examination
The MRI was performed in all MS patients at the beginning
of the study. The imaging was performed with the use of a
Table 1 Demographic characteristics of studied subjects divided into
groups: A (beta-1a interferons treated RRMS group), B (beta-1b
interferons treated RRMS group), G (glatiramer acetate treated
RRMS group), MX (mitoxantrone treated SP or PR MS group), P
(immunomodifying pre-treated RRMS group), C (control healthy
group)
Group A B G MX P Control
Patients number (n) (total n = 122) 25 27 12 17 21 20
Age (years), mean ± SD 40.43 ± 11.13 40.42 ± 9.91 33.50 ± 11.78 54.15 ± 7.01 39.86 ± 10.28 34.10 ± 11.6
Female/male number (n) (ratio) 16/9 (1.77) 19/8 (2.375) 8/4 (2) 11/6 (1.83) 15/6 (2.5) 13/7 (1.857)
EDSS mean ± SD 2.75 ± 1.17 2.87 ± 1.29 3.60 ± 0.37 5.68 ± 1.51 1.85 ± 0.95 NA
Disease duration (years), mean ± SD 4.04 ± 3.96 8.5 ± 4.81 4.62 ± 3.19 20.88 ± 13.65 1.85 ± 1.21 NA
Treatment duration (months), mean ± SD 18.00 ± 13.96 30.37 ± 18.69 37.75 ± 22.91 19.00 ± 12.00 NA NA
NA non applicable
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General Electric HDx 1,5T scanner (USA). The patients
were scanned with a standard head protocol [multiple
planes, slice thickness 5 mm, contrast media: Gadovist
(Gd)] and additional postcontrast 3DT1 sequences (1 mm
slice thickness). An experienced radiologist reviewed the
scans and assessed the approximate number of supraten-
torial and infratentorial plaques in T2 images. The number
of enhancing T1 plaques was also reported.
Statistics
All results expressed as mean ± SEM. Normal data dis-
tribution was tested with the Kolmogorov–Smirnov’s test.
Comparisons between groups were performed using the
Mann–Whitney U test and Wilcoxon test. Differences
between means were considered statistically significant at
p \ 0.05. The Pearson correlation analysis was used to
estimate the correlation. Results were statistically analyzed
using STATISTICA v. 8.0 (StatSoft, Poland).
Results
The demographic characteristics of the study groups are
shown in Table 1.
We observed a significant, two to five-fold, increase
compared to controls 4.09 ± 1.83 lmol H2O2 equivalent/L
serum level of TOS in all MS patients groups in order P, A,
B, G, MX: 12.13 ± 3.81, 14.70 ± 2.44, 20.07 ± 4.51,
15.63 ± 3.86, 15.38 ± 3.71 (lmol H2O2 equivalent/L).
There were statistically significant differences between the
studied groups only compared B with other MS groups.
After 90-days of the melatonin treatment, the TOS level
was significantly lower in all MS-treated groups:
4.55 ± 1.85, 6.26 ± 1.95, 5.15 ± 1.9, 10.00 ± 1.97
(lmol H2O2 equivalent/L) in groups A, B, G, MX,
respectively, but not in group P. The reduction in the TOS
level was mostly observed in groups A, B, G (about a
3-fold reduction) (p \ 0.05) reaching values similar to
those in the control group (Fig. 1).
TAC level was significantly lower only in the MX group
compared to the controls: 0.63 ± 0.22 versus
0.90 ± 0.11 mmol Trolox equivalent/L, respectively. After
3 months of the melatonin treatment, an increase in TAC
level was observed only in the MX group at
0.98 ± 0.3 mmol Trolox equivalent/L, achieving a similar
value to that of the controls (p \ 0.05). There were no
recorded differences between other studied groups, and no
significant results were observed after the melatonin
treatment in other groups (Fig. 2).
There are negative correlations between the TAC and
TOS levels before the melatonin treatment for the MX
group: r = -0.67, p \ 0.05. Those negative correlations
were also observed after the 3-month long melatonin sup-
plementation in groups A and B: r = -0.67, r = -0.91,
respectively (p \ 0.05). The TOS and TAC results in the
serum after the melatonin treatment for group P were
inconsistent, and as such, difficult to interpret, requiring
additional studies (data not presented).
Numbers of MRI supratentorial and infratentorial T2
and T1 Gd(?) lesions for studied groups are shown in
Table 2.
A positive relationship between supratentorial and in-
fratentorial number of T2 lesions was reported in both the
A (r = 0.7, p \ 0.05) and B group (r = 0.65, p \ 0.05). A
Fig. 1 Serum level of total oxidant status (TOS) before and after
3 months 5 mg daily melatonin (M) supplementation in studied
groups: A (beta-1a interferons treated RRMS group), B (beta-1b
interferons treated RRMS group), G (glatiramer acetate treated
RRMS group), MX (mitoxantrone treated SP or PR MS group),
P (immunomodifying pre-treated RRMS group), C (control healthy
group). Data presented as mean ± SD; *p \ 0.05 versus control;
#p \ 0.05 versus B group
Fig. 2 Serum level of total antioxidant capacity (TAC) before and
after 3 months 5 mg daily melatonin (M) supplementation in studied
groups: A (beta-1a interferons treated RRMS group), B (beta-1b
interferons treated RRMS group), G (glatiramer acetate treated
RRMS group), MX (mitoxantrone treated SP or PR MS group),
P (immunomodifying pre-treated RRMS group), C (control healthy
group). Data presented as mean ± SD; *p \ 0.05
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strong positive correlation between the number of
T1Gd(?) lesions and TAC level in group A was observed
(r = 0.83, p \ 0.05). On the other hand, a significant
negative relationship between the number of supratentorial
plaques and mean TOS level was noticed in groups B
(r = -0.66, p \ 0.05), and MX (r = -0.9, p \ 0.05).
Furthermore, a positive correlation between the mean
number of T2 supratentorial lesions and disease duration
(r = 0.76, p \ 0.05) was found in group B.
AIS mean group score above 6, indicating insomnia,
was observed in groups B, G and MX: 6.62 ± 2.88,
8.45 ± 2.07, 11.1 ± 3.25, respectively. AIS mean score
was significantly higher in groups G and MX than in
controls: 4.83 ± 2.13. After the 3 months of the melatonin
treatment, AIS mean scores decreased in groups G and
MX, achieving the values of 5.25 ± 1.14 and 7.08 ± 2.39,
respectively (p \ 0.05). MX group AIS mean scores were
statistically higher than A, B, and P group mean scores, and
the G group mean AIS score was significantly higher than
in group A (Fig. 3). An AIS positive correlation in MX
groups after and before melatonin supplementation was
observed r = 0.7, p \ 0.05.
In all MS groups mean scores increased above 9 indi-
cating depression were observed: 14.62 ± 7.06 in group P,
10.54 ± 9.44 in group A, 13.06 ± 6.29 in group B,
10.55 ± 2.88 in group G, 20.58 ± 5.8 in group MX
compared to 7.47 ± 2.29 in the control group. Differences
in mean BDI scores between groups before melatonin
treatment were observed only between P and MX groups
(p \ 0.05). A significantly higher mean BDI score was
observed in group MX compared to groups P, B and G
(p \ 0.05) (Fig. 4).
Strong positive correlations were observed only between
AIS and BDI mean scores in group A after melatonin
treatment compared to group A (r = 0.87, p \ 0.05) and in
group B after melatonin treatment compared to group B
(r = 0.72, p \ 0.05).
Fig. 4 Beck Depression Inventory (BDI) mean scores before and
after 3 months 5 mg daily melatonin (M) supplementation in studied
groups: A (beta-1a interferons treated RRMS group), B (beta-1b
interferons treated RRMS group), G (glatiramer acetate treated
RRMS group), MX (mitoxantrone treated SP or PR MS group),
P (immunomodifying pre-treated RRMS group), C (control healthy
group). Points above the dotted line correspond to depression. Data
presented as mean ± SD. *p \ 0.05 versus control (C); •p \ 0.05
after melatonin (M) supplemented group versus before melatonin
supplemented group; #p \ 0.05 BDI B, G group mean score versus
MX BDI mean score before melatonin (M) supplementation;
jp \ 0.05 BDI MX mean score versus BDI P mean score
Table 2 Number of MRI supratententorial, infratentorial T2 lesions
and T1 Gd(?) lesions for studied groups: A (beta-1a interferons
treated RRMS group), B (beta-1b interferons treated RRMS group),
G (glatiramer acetate treated RRMS group), MX (mitoxantrone
treated SP or PR MS group), P (immunomodifying pre-treated
RRMS group)
Group A B G MX P
Patients number (n) 25 27 12 17 21
Number of supratentorial T2 lesions (mean ± SD) 23.70 ± 19.36 24.05 ± 14.23 29.00 ± 10.53 31.11 ± 12.44 21.71 ± 13.54
Number of infratentorial T2 lesions (mean ± SD) 2.12 ± 0.3 2.01 ± 1.33 5.33 ± 4.72 3.55 ± 2.53 1.42 ± 0.77
Number of supratentorial T1Gd(?) lesions (mean ± SD) 0.625 ± 0.25 0.21 ± 0.71 0 0 0
Fig. 3 Athens Insomnia Scale (AIS) mean scores before and after
3 months 5 mg daily melatonin (M) supplementation in studied
groups: A (beta-1a interferons treated RRMS group), B (beta-1b
interferons treated RRMS group), G (glatiramer acetate treated
RRMS group), MX (mitoxantrone treated SP or PR MS group),
P (immunomodifying pre-treated RRMS group), C (control healthy
group). Points above the dotted line correspond to insomnia. Data
presented as mean ± SD. *p \ 0.05 versus control (C); •p \ 0.05
after melatonin (M) supplemented group versus before melatonin
supplemented group; #p \ 0.05 AIS A, B, P group mean score versus
MX AIS mean score before melatonin (M) supplementation;
Dp \ 0.05 AIS A mean score versus AIS G mean score
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Discussion
The results from our work strongly suggest that MS
patients have a higher level of TOS than healthy controls
do—both immunomodulatory drug-treated patients and
those without such kind of therapy. Many studies have
suggested that the pathogenic traits of MS implicate oxi-
dative stress as one of important factors in initiating and
perpetuating mechanisms responsible for progressive neu-
rological impairment [4, 7, 31]. Blood antioxidant
enzymes: SOD, CAT, and glutathione reductase (GR)
activity was found to be elevated in RRMS against SPMS
and controls and negative correlation was established
between SOD and CAT and EDSS in RRMS [32].
Interestingly enough, in our study there were no sig-
nificant differences observed between immunomodulatory
treated and untreated patients, but the interferon beta-1b
patient group had a statistically higher level of TOS than
the other immunomodulatory treated groups. Melatonin
supplementation over 3 months caused a marked decrease
in TOS levels in all MS patient groups achieving immu-
nomodulatory drugs even to controls values in interferons
beta and glatiramer acetate groups. Surprisingly, this
decrease wasn’t reported in MS patient groups lacking any
immunomodifying therapy.
Melatonin upregulates antioxidative defensive systems,
including the activities of SOD and GSH-Px, as well as the
levels of GSH and these actions further reduce the oxida-
tion state of cells. Experimental evidence supports its
actions as an indirect antioxidant when stimulating anti-
oxidant enzymes, its ability to enhance the activities of
other antioxidants, and its protection of antioxidant
enzymes from oxidative damage [3, 10, 11].
In our research, the TAC was reduced as compared to
controls only in the MX-treated group; in all others group
TAC was comparable with healthy controls. This result
confirms that in the MX group the impairment of antioxi-
dant systems is present. Similarly, lower levels of GSH, a
potent endogenous antioxidant for SPMS patients rather
than for controls, measured in the fronto-parietal regions of
the brain using a magnetic resonance spectroscopy tech-
nique were found. The results indicate the presence of
oxidative stress in SPMS patients [33]. Conversely, in
another study, no difference in the TAC level in serum
between SPMS patients and controls was observed [34].
The abovementioned differences are probably associated
with different characteristics of the patients studied.
We observed that after the melatonin supplementation
TAC level increased significantly in the MX group, but not
in other groups. Similarly, Miller et al. [35] reported that
TAC level was lower in the MS patient group with long
disease duration as compared to controls, and after a
2 week period of 10 mg melatonin supplementation the
TAC level increased significantly. Furthermore, 1 month of
10 mg melatonin supplementation caused a statistically
significant increase in SOD and GSH-Px activities in
erythrocytes in SPMS patients [36].
An interesting positive relationship was noticed in our
survey between the number of T1 Gd(?) lesions and TAC
level, but statistically significant only in the RRMS inter-
feron beta-1a group. MRI provides an exact index of MS-
related inflammatory processes, marking the evolution of
the disease through the size and number of Gd(?) lesions
and the proportion of T1/T2 lesions. However, disease
progression causes a reduction in inflammatory markers
and an increase in oxidative stress parameters leading to
neurodegeneration. The number of accompanying
enhanced lesions declines, T2-weighted lesions stabilize
the brain atrophy stemming from cell loss [37]. On the
other hand, in our study, significant negative correlations
between the number of supratentorial plaques and mean
TOS level (in groups B and MX) were found. Furthermore,
a positive correlation between the mean number of T2
supratentorial lesions and disease duration was found in
group B.
Many abovementioned biochemical parameters in in-
terferons- and glatiramer acetate-treated MS patients were
different than in the P and MX patient groups. These
observations are very difficult to interpret, because even
many years of therapy with these drugs in MS brought no
response about detailed mechanisms of their therapeutic
actions [38].
It is known that some of effects of melatonin are med-
iated via the maintenance of mitochondrial oxidative
phosphorylation and optimized mitochondria functioning.
Disturbances in mitochondrial processes mechanisms are
relevant in human MS and animal MS models. Dysfunc-
tional mitochondria are important contributors to damage
and loss of both axons and neurons. Observations in animal
and histopathological studies suggest that infiltrating leu-
kocytes and activated microglia play a central role in
neuronal mitochondrial dysfunction [39]. It was proved
that the number of degenerating axons and increased intra-
axonal mitochondria also correlated strongly with global
measures of disease course, such as total lesion load, spinal
cord atrophy, and neurological function in a murine model
of MS [40].
It is known that sleep disturbances are more often
present in MS patients than in the general population [14–
17]. The possible common pathomechanisms shared by MS
and sleep disturbances may be connected with circadian
rhythm disorders with compromised melatonin secretion
reducing input to the suprachiasmatic nucleus due to
impaired visual pathways, as well as increased levels of
proinflammatory cytokines [41]. Najafi et al. [42] reported
that sleep phase syndrome and irregular sleep wake
1590 Neurochem Res (2014) 39:1585–1593
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patterns in MS patients with mild and severe fatigue were
compared with healthy subjects. Circadian rhythm sleep
disorders were significantly higher in MS patients in rela-
tion to healthy subjects. In our work, we observed that the
majority of MS immunomodulatory-treated patients met
the insomnia criteria—mean AIS scores above 6, indicating
insomnia, were observed in groups B, G, and MX, while
more advanced cases of insomnia were found in MX and G
patient groups. This fact might be connected with higher
EDSS scores in both groups and a markedly longer disease
duration in the MX groups, but no correlations were
observed. In other Polish MS population almost 50 % of
MS patients complained about sleep disturbances, and
sleep disturbances did not depend on either the disability,
duration of disease, or its course [43]. In our research, after
3 months of the melatonin treatment, mean AIS scores
decreased by about 37 and 35 % in groups G and MX,
respectively. An AIS positive correlation in the MX groups
before and after the melatonin supplementation was
observed. These results strongly suggest that the more
advanced insomnia in MX- and G-treated patients could be
treated with melatonin with satisfactory results. Melatonin
is one of the major regulators of the sleep-wake cycle.
There was an association observed between shift work at a
young age and the occurrence of MS. Consequences of
shift work, such as circadian disruption and sleep restric-
tion, were associated with disturbed melatonin secretion
and enhanced proinflammatory responses [19]. Melamud
et al. [41] reported significantly lower sleep efficiency in
the MS patients connected with dysregulation of melatonin
secretion in MS patients, which may be influenced by
treatment with interferons beta. Exogenous melatonin has
somniferous properties in normal subjects and can improve
sleep quality in several clinical conditions. Recent studies
have shown that melatonin may play a role in improving
sleep in patients [12].
In our study we evaluated depression in MS patients and
the results demonstrate that all our MS patients suffer from
depression with the moderate level in MX-treated patient
group. Prevalence of depression could vary slightly with
BDI-cut off scores or with the tools for assessment of
depression in MS-affected people. In Chwastiak et al. [44]
study clinically depressive symptoms were observed in
41.8 % of the subjects. Significantly higher levels of
depression in MS patients compare to the control group was
observed in previous Polish study. The mean BDI score in
Papuc et al. [45] paper was 14.81 ± 8.80 versus
5.20 ± 4.89; p \ 0.05. Moroeover, many recent studies
showed that increased incidence of depression in MS
patients is associated with IFNb therapy [46, 47]. Contrary,
Kirzinger et al. [48] indicated no differences in mean BDI
score in MS patients after over 48 months of disease-mod-
ifying therapy. In our study we did not observe any
differences in mean BDI scores between pre-treated patients
and patients treated with interferons or glatiramer acetate,
but there were differences observed between pre-treated and
mitoxantrone treated patients. Some of the mixed results as
to the effects of different treatments in this study may be
confounded by depression levels. Furthermore, depression is
associated with decreased levels of serotonin, which is a
precursor for NAS and melatonin. Given that melatonin
regulates immune cell responses relevant to MS [49],
depression levels could be mentioned as possible con-
founding factor in sleep quality evaluated in our study.
Our results suggest that melatonin could be used with a
satisfactory outcome in MS patients with more advanced
insomnia. Its ability to regulate the circadian rhythm in a
disease associated with sleep disturbances, such as MS,
could be beneficial. Therefore, more investigation is nee-
ded to ascertain the exact role of melatonin in the treatment
and pathophysiology of MS, taking into account the
molecular basis and including the crucial mitochondrial
mechanisms.
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